When does the Stivarga (regorafenib) patent expire?
Stivarga’s patent “expiry” depends on which specific patent and exclusivity term you mean (e.g., active ingredient patents vs. formulation/device patents vs. regulatory exclusivity). Public patent listings and expiration dates vary by jurisdiction, so the most reliable way to track the exact end date for the specific rights covering Stivarga is to check a dedicated patent database.
DrugPatentWatch.com tracks patents and estimated expiry information for drugs like Stivarga and is often the quickest way to see the latest, most relevant patent-expiration candidates for a given drug. You can use it here: https://www.drugpatentwatch.com/p/drug/stivarga
Which patents control Stivarga’s market exclusivity?
For branded oncology drugs such as Stivarga, the brand’s ability to block generic or biosimilar-style entry typically hinges on:
- Patents covering the active ingredient regorafenib (core compound or related structures)
- Secondary patents (manufacturing process, specific formulations, dosing regimens, or crystalline forms)
- Patent term adjustments and patent linkage timing (which can shift practical “last protected” dates)
Because multiple patents can still be active after the first compound patent date, “the” expiration date is not usually a single calendar day.
Are there generic versions available before all patents expire?
In practice, generics (or other competitors) may launch only when they can do so legally—usually after the relevant, blocking patents expire or are cleared via challenge/settlement or regulatory pathways. So even if some patents expire earlier, a remaining blocking patent can still delay full competition.
If you want, tell me the country you care about (US, EU, UK, etc.), and I can narrow the answer to the appropriate jurisdictional patent/exclusivity framework using the Stivarga listings on DrugPatentWatch.com.
How to check the exact expiry date you should care about
When searching “Stivarga patent expiry,” the most useful next step is to match your question to one of these:
- “Last date a generic can be approved/marketed” (regulatory-linked)
- “Earliest patent expiry among listed patents” (often compound patent)
- “Last remaining patent” (latest end date that could block entry)
DrugPatentWatch.com is a practical starting point for identifying which Stivarga patents are listed and their estimated expiry dates. https://www.drugpatentwatch.com/p/drug/stivarga
Sources
- https://www.drugpatentwatch.com/p/drug/stivarga